1.	First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA183-002, NCT00389155
2.	Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: L0070 IN 302 P1, CA183004, NCT00315237
3.	Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: L00070 IN 308 B0, NCT01091168
4.	Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: L00070 IN 305 B0, 2008-004171-21, NCT01095003
5.	Pazopanib and Vinflunine in Urothelial Cancer of the Bladder Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: DZITM1, NCT01265940
6.	Phase II Study of Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium That Relapsed or Progressed After Prior Platinum-Based Chemotherapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BMS-CA183001, UPCC-07804, NCT00101608
7.	A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: I-05-009, NCT00251446
8.	Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI LUN 122, NCT00284154
9.	Vinflunine Plus Trastuzumab in HER2 Over-Expressing Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI BRE 89, CA183014, NCT00284180
10.	Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000536545, NCCTG-N0632, N0632, NCT00450515
11.	Vinflunine in Hormone Refractory Prostate Cancer (HRPC) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI GU 35, NCT00545766
12.	JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin Phase: Phase II Type: Treatment Status: Closed Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: L00070 IN 213 P1, NCT01599013
13.	A Study of the Alternative Administration of Ixabepilone and Vinflunine Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA183-008, NCT00362830
14.	Effect of Ketoconazole on the Pharmacokinetics of Vinflunine Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA183-009, NCT00388557
15.	Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: LCCC 0509, CDR0000550148, UNC-LCCC-0509, LCC 0506, NCT00320073
16.	JAVLOR® Online Non-Interventional Trial Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: JONAS-1, NCT01103544